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Adipocyte fatty acid binding protein, aP2, present in macrophages has been
implicated in the integration of lipid metabolism and inflammatory response, contributing
to development of insulin resistance and atherosclerosis. We investigated the modulation
of aP2 expression by inflammatory insults and fatty acids in RAW 264.7 macrophages.
When the cells were incubated with lipopolysaccharides (LPS; 100 ng/ml) or 10 ng/ml of
tumor necrosis factor α for 18 h, aP2 mRNA and protein levels were drastically
increased. Unsaturated fatty acids (100 μM of 18:1, 18:2, 18:3, 20:5 in complex with
BSA), but not saturated fatty acids (16:0), significantly repressed the basal aP2
expression and abolished induction of aP2 expression by LPS. Trichostatin A (TSA), a
histone deacetylase (HDAC) inhibitor, increased aP2 mRNA levels but abolished the
repressive effect of 18:2 on aP2 expression in unstimulated and LPS-stimulated
macrophages. Cells transfected with siRNA targeting aP2 showed a relationship with
cyclooxygenase-2 (COX-2), but not other pro-inflammatory mediators. In summary, our
data suggest that unsaturated fatty acids may inhibit the basal as well as LPS-induced aP2
expression by mechanisms involving HDAC in RAW 264.7 macrophages and that there
may be a link between COX-2 and aP2-repression by unsaturated fatty acids.
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Introduction
The link between lipid metabolism and inflammatory pathways has been
suggested as a significant component in the development of insulin resistance,
atherosclerosis, and type 2 diabetes (1-3). Dietary fat is an important macronutrient for
the growth and development of all organisms (4). Excessive levels of dietary fat or an
imbalance of saturated versus unsaturated fat have been implicated in the onset and
progression of several chronic diseases, including coronary artery dieses, atherosclerosis,
diabetes, obesity, and cancer (4). Specifically, unsaturated fatty acids are known to have
positive health benefits such as reductions in atherosclerosis, inflammation, and plasma
free fatty acid levels (5). However, the mechanisms for the anti-inflammatory properties
of unsaturated fatty acids are poorly understood.
Fatty acid binding proteins (FABP) are implicated as players in the
inflammatory response as well as lipid signaling cascades (2, 3). FABP are intracellular
lipid chaperones that have a role in import, storage, and export of fatty acids because they
reversibly bind hydrophobic ligands, such as saturated/ unsaturated long-chain fatty acids
with high affinity (2).
The most characterized FABP is adipocyte fatty acid binding protein
(aP2/FABP4), which is found in adipocytes at high levels and in macrophage cells to a
lesser extent (2). Studies have shown that aP2 deficiency gives partial protection against
atherosclerotic lesion formation in apolipoprotein E knockout mice, as well as, systemic
insulin resistance, dyslipidemia, and lipotoxicity in aP2 -/- ob/ob mice (2, 6).
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The chronic low-grade inflammation associated with obesity is perpetuated by
macrophage infiltration into lipid-engorged adipose tissue; this results in a release of
various inflammatory cytokines (7, 8). Accompanying an obesity-induced inflammatory
state are elevated circulating levels of aP2 (9).
The majority of research on the regulation of aP2 expression has been in
adipocytes. Various cis-acting elements of the aP2 gene have been suggested, including
an activator protein -1 (AP-1) sequence, and CAAT/enhancer-bind protein (C/EBP)
binding element (10, 11). Recently it was demonstrated that macrophage aP2 can be
regulated by phorbol 12-myristate 13- acetate, lipopolysaccharide, oxidized low-density
lipoprotein and PPARγ ligands (12).
One way to affect gene expression is through the involvement of coactivator/
corepressor complexes (13). Histone deacetylases (HDAC) are essential components of
co-repressor complexes as they provide the enzymatic activity for active repression(14).
HDAC are a class of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino
acid on a histone. Its action is opposite to that of histone acetyltransferase (HAT) (15).
Removal of acetyl groups gives chromatin a tightly-bound structure that prohibits
transcription. Inclusion of acetyl groups decreases the affinity of histones for DNA and
allows transcription to occur (15). There are eighteen known HDAC, which are divided
into four classes. Class 1 HDAC are generally detected in the nucleus and ubiquitously
expressed. Specifically, HDAC3 is unique among class 1 HDAC in that it can shuttle
between the nucleus and cytoplasm and form complexes(15). Transcription factors that
have been shown to interact with the corepressor complex for repressive effects on gene
transcription include: AP-1 (16-18), nuclear factor κB (NF-κB) (16, 17, 19), liver X
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receptor α (20), and thyroid hormone receptor (13, 21, 22). Upon activation, the corepressor complex is exchanged with co-activators that lead to transcription (14).
Here we demonstrate histone modification involving HDAC as a mechanism for
how fatty acids can affect aP2 expression in murine RAW 264.7 macrophage. Though
therapeutic drugs are currently being developed to exploit aP2 for the treatment of
diabetes and atherosclerosis (3, 12), the mechanisms for how aP2 expression is controlled
under basal and activated conditions in macrophage is still unknown. Elucidation of aP2
regulatory mechanisms would allow for more accurate manipulation of pathways by
dietary or pharmaceutical agents in order to positively influence health status.
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Literature Review
Obesity and Inflammation
Obesity, which is defined as a body mass index (BMI) greater than or equal to 30
kg per m2, predisposes an individual to develop insulin resistance, cardiovascular disease,
diabetes, hypertension, high cholesterol, stroke, and certain cancers (23-25). The obesity
epidemic reached a peak in 2003, and currently more than one-third of adults over age 20
in the United States are considered obese (24). Much of the complications associated
with obesity are thought to be a product of the accompanying chronic inflammatory state
in the adipose tissue (1, 7, 23, 25).
Adipose tissue is now being recognized as an endocrine organ, due to its ability to
release pro- and anti-inflammatory protein factors, known as adipokines (26, 27). A
chronic inflammatory response, characterized by elevated adipokine production and the
activation of some pro-inflammatory signaling pathways, causes an induction of several
biological markers of inflammation (28). These variations in gene expression of white
adipose tissue are attributed to the infiltration of monocytes into lipid-engorged adipose
tissue, which has been seen in both mouse models of obesity and obese humans (8, 28).
It has been proposed that monocyte chemoattractant protein- 1 (MCP-1) (8), leptin (29),
or activated endothelial cells (29, 30) could contribute to the macrophage infiltration into
adipose tissue. Macrophages in the adipose tissue are responsible for most of the locallyproduced cytokines such as tumor necrosis factor α (TNFα) and interleukin-6 (IL-6).
TNFα is known to interfere with energy metabolism, especially lipid homeostatis by
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increasing free fatty acid production (31). In vitro studies using adipocyte cell lines
support the role of IL-6 as a factor to cause insulin resistance in adipocytes (32).
It is believed that the increases in local cytokine production from macrophage in
lipid-engorged macrophages is the cause or possibly the consequence of the low-grade
inflammation associated with obesity (28, 33, 34). The connection between adipose tissue
and the immune system is clear, but why such a link exists is up for speculation.
Coppack postulates that with the immune system using about 15% of resting metabolic
rates, it would need to have a link to the availability of energy, especially the size of the
adipose energy stores (35). This idea gives evolutionary purpose to the cross-talk
between the immune and metabolic systems.

Inflammatory Signaling Pathways
Toll-like receptors (TLRs) play a critical role in the activation of the innate
immune response in mammals by recognizing conserved pathogen-associated molecular
patterns on invading bacteria (36). There are currently 13 known members of the TLR
family in mammals, with TLR4 being a subclass (36). TLR4 can be activated by
lipopolysaccharide (LPS), originating from the outer-membrane of gram negative
bacteria, and non-bacterial agents such as saturated fatty acids (36, 37). The activation of
TLR4 induces upregulation of intracellular inflammatory pathways such as c-Jun NH2 –
terminal kinase (JNK) , nuclear factor –κB (NF-κB), and mitogen activated protein kinase
(MAPK) pathways. The MAPK pathway can then lead to activation of the transcription
factor activating protein 1 (AP-1) (36, 38).
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TLR signaling in response to pathogen contact can contribute to the development
of atherosclerosis (38). Loss of TLR4 leads to a protection against diet-induced obesity, I
Kappa B Kinase β (IKKβ), and JNK expression, and insulin resistance (36). Activation of
TLR4 by saturated fatty acids, not unsaturated fatty acids, can induce the expression of
cycloxygenase-2 (COX-2), a marker for inflammation (39). Tsukuma et al. have
suggested TLR4 may be a candidate for participation in insulin resistance induced by a
saturated fatty acid-rich diet (36). It has been observed that saturated fatty acids can
directly interact with the immune modulation and inflammation response through the
activation of TLRs in macrophage (39).
Activation of the innate immune system can also be a result of TNFα. Binding of
TNFα to its cell surface receptor induces the inflammatory response. TNFα is a major
adipokine and its expression is highly induced in obesity (32, 35). It is known to interfere
with insulin signaling after receptor binding on muscle cells or hepatocytes (32). TNFα
causes an increase in free fatty acids, which encourage the development of insulin
resistance in persons with metabolic disorders (31). Activation of a macrophage by either
LPS or TNFα leads to downstream convergance onto similar inflammatory pathways.
One route is through the IKK which signals the NF-KB pathway(40). Secondly, is
through JNK and the AP-1 pathway (40).

Peroxisome Prolifeator Activator Receptor γ
PPAR is a ligand-activated member of the nuclear receptor super family known
to be involved in gene regulation of inflammatory and metabolic pathways (41, 42).
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PPARγ was initially discovered as the master regulator in adipose cells (43). It is
essential for the regulation of adipogenesis and is required for maintenance of mature
adipocyte function, including triglyceride synthesis and storage (43-45). PPARγ is also
expressed in activated monocytes/ macrophage and its agonist can inhibit the production
of inflammatory cytokines by antagonizing the activities of transcription factors such as
AP-1 and NF-κB (46, 47). One such antagonizing mechanism is through the liganddependant sumoylation of the PPARγ ligand-binding domain which inhibits the removal
of a repressor complex from inflammatory gene promoters (14, 48). Alternatively, antiinflammatory PPARγ activity can be inhibited by TNFα and this inhibition is thought to
be involved in the pathogenesis of insulin resistance, atherosclerosis, and inflammation
(6, 49). Naturally occurring ligands for PPARγ include long-chain fatty acids; other
known synthetic PPARγ ligands include the thiazolidinedione class of anti-diabetic drugs
(43). It is unclear as to whether aP2 enhances or inhibits the transcriptional activity of
PPAR , as experiments showing both have been reported (50, 51). A culmination of
recent data suggests PPAR agonists may regulate inflammation by the activation of
PPAR or alternatively through a PPAR -independent mechanism (42, 44).

NF–κB Pathway
Production of pro-inflammatory cytokines is regulated largely by NF-κB (40, 42,
52, 53). It plays a pivotal role in the regulation over 100 genes, including TNFα, MCP-1,
and cyclooxygenase 2 (COX-2) (54). In the canonical NF- B pathway, p65 and p50
form a dimer and its activation is regulated by kappa B inhibitor protein (I B) (14).
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Following stimulation by inflammatory stimuli such as LPS, rapid proteasomeal
degradation of I B occurs after being phosphorylated by I B kinase (IKK) (40). This
allows NF- B to shuttle from the cytoplasm into the nucleus, where it then promotes the
transcription of target inflammatory genes (40).
Dietary agents have been shown to affect the NF-κB pathway. Fraxinellone,
derived from root bark of Dictamnus dasycarpus, inhibits LPS-induced inflammatory
response by negatively regulating NF-κB in RAW 264.7 macrophages (55). In contrast,
in vitro culture of monocytes under high glucose condition compared to normal glucose
led to the activation of NF-κB and significantly increased the expression of inflammatory
cytokines including TNFα and MCP-1 (54).

MAPK and AP-1 Pathway
Upon binding of a peptide:MHC complex to a T-cell receptor, a cascade of
proteins initiate the activation of the MAPK pathway (56). In the MAPK pathway, a
three-kinase relay system, or MAPK cascade, involves three phosphorylation events that
can lead to new gene transcription (56). The three most characterized groups of MAPK
are extracellular signal-regulated kinases (ERK), p38 MAPK, and JNK (57). ERK are
robustly activated by growth factors and phorbol esters but only weakly activated by
cytokines and environmental stress (57). In contrast, p38 MAPK and JNK are strongly
activated by cytokines and environmental stress but are poorly activated by growth
factors and phorbor esters (57, 58). ERK works with the transcription factor Elk-1 to
initiate transcription of Fos, a dimer component of AP-1 (56). JNK controls
transcriptional activity of AP-1 via phosphorylation of c-Jun, allowing translocation of c-
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Jun to the nucleus (56, 58). In the nucleus, c-Jun can dimerize with Fos to form AP-1
(56). In LPS-induced macrophages, phosphorylation of JNK was shown to initiate an
inflammatory responses (59). Furthermore, JNK activity is significantly elevated in
tissues of type 2 diabetic patients and in animals of obesity and diabetes (58).
AP-1 is a transcription factor that is a heterodimer of c-Jun, c-Fos, or activating
transcription factor ATF proteins (60). It is activated by growth factors,
neurotransmitters, cytokines, and bacterial or virus infections and is known to be
involved in the transcriptional regulation of the inflammatory response (59).

Inflammatory Cytokines
Cytokines are a group of small, diverse proteins that are released by cells in the
body in response to activating stimulus, such as pathogen invasion. They induce
responses by binding to specific receptors and exert their effects in an autocrine,
paracrine, or endocrine manner (35). The cytokines secreted by macrophage include: IL1β, IL-6, IL-12, and TNF-α. IL-1β is responsible for activating vascular endothelium and
lymphocytes (56). It is the cytokine responsible for the induction of fever (56). IL-6 is
also responsible for lymphocyte activation and increases antibody production for the
adaptive immune response (56). TNFα activates vascular endothelium and increases
vascular permeability, which leads to increased entry of IgG, complement, and cells to
tissues, and increases fluid drainage to lymph nodes (56). These cytokines are commonly
used as experimental markers of an inflammatory response.
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COX- 2 and Anti-Inflammatory Drugs
Cyclooxygenase (COX) catalyses the committed conversion of arachidonic acid
to prostaglandin endoperoxide H2 (PGH2) and exists in two isoforms (61-66). These two
isoforms of COX, i.e., COX-1 and COX-2, have different amino acid sequences but
catalyze the same reaction. Both forms are membrane-bound, endoplasmic reticulum
(ER)- resident, heme-containing glycoproteins that function as homodimers (63). COX-1
is constitutively expressed in most cell types (65, 66). In contrast, COX-2 expression is
typically transient and is associated with inflammation (39, 64). The expression of COX2 is a key element in various pathological conditions including arthritis, cardiovascular
disease, and cancer (64).
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that nonspecifically target COX (61). They are prescribed for the treatment of inflammatory
diseases such as arthritis and osteoarthritis. NSAIDs had initial success; however, long
term therapy showed gastrointestinal (GI) toxicities due to the general inhibition of both
COX-1 and COX-2. COX-1 expressed throughout the GI tract has protective effects on
the GI mucosa by producing prostaglandin E2 (PGE2) (63). To avoid this side effect,
research shifted toward selective COX-2 inhibitors. Selective inhibitors for COX-2, a
class of drugs known as coxibs, show a decrease in inflammation. While, COX-2 knockout mice have a marked protection from intestinal and skin tumors (66). Conversely,
over-expression of COX-2 is observed in various malignant tissues (62). Depending on
the cell type, COX-2 expression can be rapidly induced by the bacterial endotoxin LPS,
cytokines such as IL-1, IL-2, and TNFα, and the tumor promoter, phorbol 12-myristate
13- acetate (PMA) (61). Though, even after stimulation, protein levels of COX-2 only
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reach about 50% of COX-1 (61). After initial studies on COX-2 inhibitors, concerns
arose regarding adverse cardiovascular events. Studies demonstrated that selective COX2 inhibitors tip the natural balance between prothrombotic thromboxane A2 and
antithrombotic prostacyclin, which potentially increases the possibility of thrombosis
(63). Research is on-going to find a selective COX-2 inhibitor that is not accompanied by
severe side effects.

Fatty Acids
In the western diet, lipids represent more than 40% of the daily caloric intake,
while nutritional advice recommends to limit lipid intake to 30% (26, 67). Fatty acids in
the body can be exogenously brought in from the diet or can be generated from acetylCoA in a process called de novo lipogenesis (4, 68). A high fat diet is understood to
greatly contribute to the increase of obesity prevalence as fatty acids are stored in fat cells
composing adipose tissue (69). Carbohydrate (i.e. glucose) can be converted through de
novo synthesis to fatty acids, which can also be stored in the form of triacylglycerol in
adipose tissue (68).

Fatty Acids Metabolism
Mechanisms for the absorption of fatty acids differ according to the size and
characteristic of the fatty acid. Long-chain fatty acids mix with bile acids in the intestinal
lumen to form micelle particles (70). Micelles interact with the brush border of the
intestine to allow fatty acid to diffuse from the micelle into the enterocyte, moving down
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a concentration gradient (70). Fatty acids can also enter the cell through protein
transporters, such as fatty acid transport protein (FATP) (71). From the enterocyte, fatty
acids are packaged into chylomicrons that are then excreted into the lymph system (4,
69). Conversely, small-chain fatty acids have the ability to move directly from the
intestinal lumen into portal circulation where they bind and are transported by albumin to
the liver (70).
The liver and adipose are the two most important tissues in fatty acid metabolism.
The liver is responsible for the uptake and catabolism of fatty acids as well as their
repackaging into very low density lipoprotein (VLDL) in the form of triacylglercerol
(70). The liver can also generate fatty acid from non-lipid precursors such as glucose
(68). Fatty acids are delivered to adipose cells for storage. They can be delivered by
VLDL, which would carry fatty acids originating from the liver, whereas dietary fatty
acids are delivered to adipose cells by chylomicrons (70).

Fatty Acid Structure
The basic structure of fatty acids is a hydrophobic polycarbon chain which can
vary in chain length with different degrees of saturation. Short- and medium-chain fatty
acids, those with less than 6 or 14 carbons, respectively, are mainly saturated and used
predominantly for energy supply. Long-chain fatty acids can be saturated as well as
mono- or polyunsaturated, depending on the number of double bonds. They can serve
functions apart from energy supply, including structural components of cells, gene
regulators, involvement in cell growth and differentiation, or modulation of lipid,
carbohydrate, and protein metabolism (4). The two major classes of long-chain
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polyunsaturated fatty acids (PUFA) are ω-3 and ω- 6 fatty acids, where the ω-number
indicates the position of the first double bond counted from the methyl group of the
hydrocarbon chain. Current recommendations are to consume a higher percentage of ω-3
than ω-6 PUFA (72). Linoleic acid (18:2, ω-6) is an essential PUFA and the precursor
for arachidonic acid (20:4, ω-6), while α-linoleinic acid (18:3, ω-3) is the precursor for
eicosapentaenoic acid (20:5, ω-3) and docosahexaneic acid (22:6, ω-3). PUFA contribute
roughly 7% of total energy intake in the diets of adults with linoleic acid (18:2, ω-6)
being the most abundant in the diet (72). It has been established that fatty acids,
specifically PUFA, can influence gene and protein expression (4, 26, 59, 73).
Specifically, gamma- linoleic acid, which is converted in the body from linoleic acid by
delta-6-desaturate, has the ability to inhibit the response generated by an inflammatory
insult through inactivation of inflammatory pathways in RAW 264.7 macrophage (59).
Unsaturated fatty acids, in general, are thought to have anti-inflammatory properties and
many studies have given support to their inclusion in the diet (72, 74, 75).

Adipose Fatty Acid-Bindng Protein, aP2
Fatty-acid binding proteins (FABP) are cytoplasmic proteins with low molecular
weight (~15 KDa) that bind fatty acids with high affinity in a 1:1 complex with an
interior ligand binding domain (76). They are implicated as players in the inflammatory
response as well as lipid signaling cascades (2, 3). FABP function as intracellular lipid
chaperones with a role in import, storage, and export of fatty acids because they
reversibly bind hydrophobic ligands, such as saturated/unsaturated long-chain fatty acids
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with high affinity (2, 77). There are nine known FABP identified in different cell types
(78). The most characterized FABP is adipocyte fatty acid- binding protein (aP2/FABP4)
which is found in adipocytes at high levels and in macrophages to a lesser extent (2).
Specific functions of aP2 other than a lipid chaperon are unclear; however, Thompson et
al. (76) suggested that aP2 may act as a fatty acid sensor affecting cellular metabolism
via protein-protein interactions as demonstrated by experiments involving Janus kinase 2
(JAK2) (76).
Mouse studies have shown that aP2 deficiency gives partial protection against
atherosclerotic lesion formation in apolipoprotein E knockout mice, as well as systemic
insulin resistance, dyslipidemia, and lipotoxicity in aP2 -/- ob/ob mice (2, 6). Molecular
mechanisms underlying the effect of aP2 on the pathogenesis of the diseases are still
under investigation. aP2’s involvement in these diseases may be, in part, from the ability
of an inflammatory insult such as LPS to dramatically increase aP2 expression in RAW
264.7 macrophage; triglycerides in macrophage are also increased when treated with LPS
(79). This paralleled increase suggests aP2 as an intermediary in the link between the
immune and metabolism systems. Pharmacological agents specifically targeting aP2 are
currently being investigated as a treatment for diabetes and atherosclerosis (3, 12).
An AP-1 sequence (80, 81), and C/EBP binding element (10, 11) have both been
suggested as cis-acting elements of the aP2 gene. It was demonstrated that macrophage
aP2 can be regulated by phorbol 12-myristate 13- acetate (PMA), LPS, oxidized lowdensity lipoprotein and PPARγ ligands (12). The mechanisms for how aP2 expression is
controlled under basal and activated conditions in macrophage is still unknown.

Histone Modifications
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Eukaryotic cell DNA is packaged into structures called nucleosomes (82). Each
nucleosome is comprised of eight core histone proteins and the associated wrapped DNA
(82). Histones are small, positively charged proteins and have close association with
DNA. Eukaryotic cells commonly contain five abundant histone proteins: H1, H2A,
H2B, H3, and H4 (82). H2A, H2B, H3, and H4 are considered the core histones because
two copies of each form the protein core around which the nucleosome DNA is wrapped
(82). H1 binds to the linker DNA and is referred to as a linker histone. Histone proteins
tend to have a high concentration of positively charged amino acids, including lysine and
arginine (82). By assembling into nucleosomes, DNA is approximately compacted 6fold (82). The core DNA is a 147 base pair section that is wrapped around the histone
octamer and then linked to the next histone octamer by a variable 20 – 60 base pair
region of DNA (82).
Chromatin greatly impedes transcription. Epigenetic modifications of chromatin
and DNA have been recognized as important permissive and suppressive factors in
controlling gene transcription (83). Epigenetic mechanisms result in heritable
modification in the expression of genes that are independent from DNA coding
variability (83). Two major epigenetic mechanisms are the post-translational
modification of histone proteins in chromatin and the methylation of DNA (83). Posttranslational modifications of histones include, but are not limited to, lysine acetylation,
lysine and arginine methylation, serine and threonine phosphorylation, and lysine
ubiquitination and sumoylation (84). Emerging evidence suggest a role of epigenetics in
human pathologies, including inflammation (83). Additionally, it is known that nutrition
and environment have the ability to influence the epigenetic profile.
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Histone Deacytelases
One way to affect gene expression is through the involvement of coactivator/
corepressor complexes (13). Histone deacetylases (HDAC) are essential components of
co-repressor complexes as they provide the enzymatic activity for active repression (14).
HDAC are a class of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino
acid on a histone (15). Its action is opposite to that of histone acetyltransferase (HAT)
which act as coactivators (15). Removal of acetyl groups gives chromatin a tightlybound structure that prohibits transcription. Inclusion of acetyl groups decreases the
affinity of histones for DNA and allows transcription to occur (15). There are eighteen
known HDAC, which are divided into four classes (15). Class 1 HDAC are generally
detected in the nucleus and ubiquitously expressed (15). Specifically, HDAC3 is unique
among class 1 HDAC in that it can shuttle between the nucleus and cytoplasm and form
complexes (15).
Transcription factors that have been shown to interaction with the corepressor
complex for repressive effects on gene transcription include AP-1 (16-18), NF- κB (16,
17, 19), liver X receptor α (20), and thyroid hormone receptor (13, 21, 22). Upon
activation, the co-repressor complex is exchanged with co-activators that lead to
transcription (14). Using chromatin immunoprecipitation (ChIP), it was shown that high
glucose conditions, similar to a diabetic state, could increase the recruitment of HAT to
the promoter regions of inflammatory genes such as TNFα and COX-2 and lead to
acetylation of nucleosomal factors histone H3 and H4 (54).
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HDAC inhibitors are currently under investigation as anti-cancer agents because
overexpression of HDACs has been observed in various cancers (15). Trichostain A
(TSA) is a potent and nonselective inhibitor of HDAC (15, 85). TSA treatment has been
seen to change the expression of only about 2% of genes (85). TSA is widely used to
study the role of histone acetylation on gene expression.
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Materials and Methods
Cell Culture and Fatty Acid Preparation
Murine RAW 264.7 macrophages (ATCC) were cultured in RPMI 1640
supplemented with 10% fetal bovine serum, 100 U/ml penicillin/ 100 ng/ml
streptomycin, 1x vitamins, and 2 mM L-glutamine in a humidified chamber at 37°C with
5% CO2. Cells were plated at 5 x 105 per well in a 12-well plate to extract RNA and 1.5 x
106 per well in a 6-well plate for protein extraction. All cell culture supplies were
purchased from MediaTech.
Two mmol/L of fatty acid-poor and endotoxin-free bovine serum albumin (BSA;
Calbiochem) was prepared in phosphate buffered saline (PBS). Sodium salts of fatty
acids (Nu-Chek) were dissolved in the 2 mmol/L BSA solution to a final concentration of
5 mmol/L. Fatty acids prepared included: myristic acid (14:0), palmitic acid (16:0),
palmitoleic acid (16:1), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3),
arachidonic acid (20:4), eicosapentaenoic acid (20:5) and docosahexaenoic acid (22:6).
The fatty acid and BSA mixture was purged with N2 , sonicated in a cool water bath until
the solution became clear to form BSA/fatty acid complex (approximate molar ratio =
1:2.5), filter sterilized through a Millex -GV 0.22 M filter unit (Millipore), and diluted
with cell medium to reach a final concentration of 100 mol/L.
Raw 264.7 macrophages were incubated with BSA only (control) or 100 M of a
fatty acid for 6 h followed by BSA or fatty acid with 100 ng/mL LPS. For the inhibition
of HDAC, RAW 264.7 macrophages were incubated in RPMI 1640 containing 500 nM
TSA (Sigma-Aldrich) dissolved in dimethy sulfoxide (DMSO; Sigma-Aldrich) and 100
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M fatty acids for 6 hours followed by 14 hours in RPMI 1640 containing 500 nM TSA,
100 M fatty acid, and 100 ng/ml LPS. For the experiments using the inhibitor, control
cells were incubated with the same amount of DMSO vehicle. Macrophage activation
was by LPS and TNFα. Cells were incubated with 100 ng/mL LPS (Sigma-Aldrich) or
2.5ng/ml, 5.0ng/ml, and 10ng/ml TNF (eBioscience) for 18 hours and RNA was
collected and analyzed by real-time PCR.

Small Interfering RNA (siRNA) Transfection
RAW 264.7 macrophages were transfected with Silencer Negative Control
siRNA (Ambion) (control) or Dharmacon siGenome SMART pool siRNA targeting aP2
(Thermo Scientific) for gene knockdown using DharmaFECT 1 transfection reagent
(Thermo Scientific) according to the manufacture’s protocol. . In brief, 2.5 μl of
transfection reagent DharmaFECT 1 was diluted into 97.5 l of cell medium void of
antibiotics and fetal bovine serum. Control and siRNA (2 or 3 mol/L) were prepared in
RNase-free sterile water and 50 l of the diluted siRNA solution was mixed with 50 l of
cell medium void of antibiotics and fetal bovine serum. Subsequently, the media
containing transfection agent and siRNA were combined and incubated for 20 min at
room temperature. The siRNA and transfection agent complex was then diluted to desired
volume (1 ml). When recovering protein, reaction volumes were doubled and diluted
siRNA concentration was 2.5 mol/L. Transfection occurred for 24 hours, after which
cells were incubated with 100 M fatty acids for 6 hours and then 100 M fatty acid and
100 ng/ml LPS for 18 hours.
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Total RNA Isolation and Quantitative Real-time PCR
Total RNA was extracted from cells using TRIzol reagent (Invitrogen) following
manufacturer’s protocol or using the RNeasy Kit (Qiagen). Reverse transcription for
cDNA synthesis and quantitative real-time PCR analysis were performed as previously
described (86, 87). Primers were designed according to GenBank database using the
Primer Express software (Applied Biosystems). The following primers were used for
real-time PCR analysis: GAPDH, aP2, COX2, IL-1β, IL-6, and TNFα (Table 1).

HDAC Activity
Raw 264.7 macrophages were transfected with scrambled control or aP2 siRNA
and incubated with 100 μM fatty acid for 6 h then 100 ng/ml LPS was added to fatty
acids for an additional 18 h. Nuclear extracts were collected using Nuclear Extract Kit
(Active Motif) according to manufacturer’s protocol. Protein concentration was measured
using BCA Protein Assay Kit (Thermo Scientific) and 10 g of nuclear extract was
analyzed for HDAC activity using a HDCA Activity Assay Kit (Cayman Chemical)
according to the manufacturer’s protocol.

Western Blot Analysis
Cell lysate was prepared and Western blot analysis was performed as previously
described (88). Antibodies used for analysis were as follow: aP2/FABP4 (Santa-Cruz),
and -actin (Sigma-Aldrich). -Actin was used as a loading control to normalize the data.
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Statistical Analysis
ANOVA and Newman-Keuls Multiple comparison with Welch’s correction for
unequal variance when appropriate were used to identify statistically significant
differences of treatments with P < 0.05 considered significant by GraphPad InStat 5
(GraphPad Software, Inc.). Data are expressed as mean

SEM.
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Table 1. Real-time PCR primers for mRNA expression

Forward Primer
5’  3’

Reverse Primer
5’  3’

TGTGTCCGTCGTGGATCTGA

CCTGCTTCACCACCTTCTTGAT

CACCATCCGGTCAGAGAGTACTT

CGGTGATTTCATCGAATTCCA

COX2

AAAGGTTCTTCTACGGAGAGAGTTCA

TGGGCAAAGAATGCAAACATC

IL-1β

GTCACAAGAAACCATGGCACAT

GCCCATCAGAGGCAAGGA

IL-6

CTGCAAGAGACTTCCATCCAGTT

AGGGAAGGCCGTGGTTGT

GAPDH
aP2

TNFα

GGCTGCCCCGACTACGT

ACTTTCTCCTGGTATGAGATAGCAAAT
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Results
Expression of aP2 was induced by LPS stimulation in RAW 264.7 macrophages
Raw 264.7 macrophages were treated with 100 ng/ml LPS or 2.5 ng/ml, 5.0
ng/ml, and 10 ng/ml TNF

for 18 hours to evaluate the effect of an inflammatory insult

on aP2 expression and quantitative real-time PCR analysis was conducted. LPS
drastically increased aP2 mRNA abundance by ~8-fold compared with the control
(Figure 1). Cells treated with TNF also showed a ~2-fold increase in aP2 mRNA
expression relative to the control (data not shown).

Unsaturated fatty acids (UFA) inhibited LPS-induced aP2 expression in RAW 264.7
macrophages
To investigate whether fatty acids could alter aP2 expression in response to an
inflammatory insult, RAW 264.7 macrophage were incubated with fatty acids including
myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:1), oleic acid (18:1),
linoleic acid (18:2), linolenic acid (18:3), arachidonic acid (20:4), eicosapentaenoic acid
(20:5) and docosahexaenoic acid (22:6) in the absence or presence of LPS. Consistent
with previous data in Figure 1, LPS increased aP2 expression in the BSA control.
Without LPS treatment, no significant difference in aP2 mRNA levels was seen in all the
fatty acid treatment groups (Figure 2A). In contrast, when cells were activated by LPS,
unsaturated fatty acids significantly decreased aP2 expression whereas saturated fatty
acids did not alter the expression compared with the control. Western blot analysis
confirmed the inhibition of LPS-induced aP2 protein levels by unsaturated fatty acids
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Figure 1. Elevated aP2 mRNA levels by LPS in RAW 264.7 macrophages. Cells were
treated with 100 ng/ml LPS for 18 hours, after which quantitative real-time PCR was
conducted to measure aP2 mRNA abundance. n = 9, Mean ± SEM. *, P < 0.001.
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Figure 2. Elevated aP2 expression by LPS was abolished by unsaturated fatty acids
in RAW 264.7 macrophages. Cells were treated with 100 μM fatty acid complexed with
BSA for 12 hours and subsequently activated by 100 ng/ml LPS for 18 hours. A. aP2
mRNA expression was measured by real time PCR. n=3-4, Mean ± SEM. Bars with
different letters are significantly different compared with control within the absence or
presence of LPS treatment (P < 0.05). B. aP2 protein was measured by western blot
analysis and -actin was used as a loading control.
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(Figure 2B). Palmitic acid markedly increased aP2 protein levels in the presence of LPS
despite no significant change in mRNA levels.

TSA abrogateed UFA-mediated repression of basal and LPS-induced aP2 expression
To evaluate whether alterations in histone acetylation state is involved in the
inhibitory effect of UFA on aP2 expression, RAW 264.7 macrophages were treated with
TSA, an HDAC inhibitor (15), together with fatty acids, after which aP2 mRNA levels
were quantified by real-time PCR. In consistent with our previous observations, LPS
increased aP2 mRNA levels and 18:2 significantly lowered basal as well as LPS-induced
aP2 expression in the absence of TSA (Figure 3). In the presence of TSA, however, the
repressive effect of 18:2 on basal and LPS-induced aP2expression was abolished. The
data indicate that 18:2 could inhibit basal and LPS-induced aP2 expression by modulating
HDAC.

Palmitic acid decreased HDAC activity in RAW 264.7 macrophages
To evaluate the effect of fatty acids and aP2 on HDAC activity, Raw 264.7
macrophages were transfected with scrambled control or siRNA targeting aP2 for 24 h
and then treated with 100 μM fatty acid for 24 h. aP2 protein levels were markedly
diminished by siRNA in all the groups (Figure 4A). Compared to control, 16:0
significantly reduced HDAC activity regardless of aP2 deficiency (Figure 4B). Although
knockdown of aP2 did not alter HDAC activity within each fatty acid treatment, HDAC
activity was significantly elevated by 18:2 compared with control when aP2 was
deficient.

27

Figure 3. Abrogation of repression of basal and LPS-induced aP2 mRNA levels by
TSA in RAW 264.7 macrophages. Cells were treated with 100 μM fatty acid and 500
nM TSA for 6 hours, after which 100 ng/ml of LPS was added for additional 18 hours.
aP2 mRNA levels was measured by quantitative real-time PCR analysis. n=8-9, Mean ±
SEM. *, P <0.05 compared with control in the same treatment. $, P < 0.05 compared with
18:2 in the same treatment.
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Figure 4. Inhibition of HDAC Activity by palmitic acid in RAW 264.7 macrophages.
Cells were transfected with 125 nM of scrambled control (sc) or siRNA targeting aP2 for
24 h. They were subsequently treated with 100 μM fatty acid for 6 h after which 100
ng/ml LPS was added for additional 18 h. A. Nuclear extracts were collected to measure
HDAC activity n = 4, Mean ± SEM. B. Cytoplasmic fractions were subjected to Western
blot analysis to assess aP2 knockdown. β-actin was used as a loading control.
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COX-2 was repressed by aP2 knockdown in LPS- stimulated RAW 2647 macrophages
To investigate whether aP2 plays a role in in the repressed pro-inflammatory gene
expression by unsaturated fatty acids, RAW 264.7 macrophages were transfected with
scrambled control or aP2 siRNA to knockdown aP2 expression. Cells were then treated
with 100 μM of 16:0 and 18:2 for 6 h, after which 100 ng/ml LPS was added to cell
culture medium to activate macrophages for 18 h. Real-time PCR analysis was performed
to measure mRNA levels of aP2 and pro-inflammatory markers including IL-1β, IL-6,
TNFα, and COX-2. aP2 mRNA levels showed a reduction by 75-80% by siRNA
transfection (Figure 5) . In the unstimulated macrophages, deficiency of aP2 by siRNA
increased the pro-inflammatory mediator expression and the increase was drastic
particularly in 16:0-treated cells (Figure 6). In contrast, when cells were stimulated by
LPS, aP2 knockdown had a minimal effect on IL-1 , TNF and IL-6 mRNA levels. Of
interest was that COX-2 mRNA abundance were significantly reduced when aP2 was
deficient.
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Figure 5. Knockdown of aP2 using siRNA in RAW 264.7 macrophages. Cells were
transfected with 100 nM of scrambled control or aP2 siRNA and then treated with 100
μM fatty acid for 6 h. Subsequently, cells were activated by 100 ng/ml of LPS for 18 h.
aP2 mRNA levels were measured by real-time PCR. n= 3, Mean ± SEM
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Figure 6. Effect of aP2 and FA on pro-inflammatory gene expression in RAW 264.7
macrophages. Cells were transfected with 100 nM of scrambled control or aP2 siRNA
and then treated with 100 μM fatty acid for 6 hours. Subsuquently, cells were activated
by 100 ng/ml of LPS for 18 hours. Expression of pro-inflammatory mediators including
IL-6, IL-1β, TNFα and COX-2 were measured by real-time PCR. n = 3, Mean ± SEM.*,
P <0.05 compared with scrambled control in the same fatty acid treatment. #, P < 0.05
compared with BSA control.

32

Discussion
aP2 deficiency in mice led the protection against the development of IR (89-91).
Total and macrophage-specific aP2 knockout mice showed a marked reduction in
atherosclerotic lesion formation in apolipoprotein E knockout (apoE-/-) mice (92-95). In
humans, a functional genetic variant of aP2 gene, resulting in reduced aP2 expression,
showed a significantly lowered risk for Type 2 diabetes and CVD (96). Additionally,
administration of an aP2 inhibitor in ob/ob and apoE-/- mice reduced the development of
type 2 diabetesand atherosclerosis, respectively (12). The health benefits from absence or
reduction of aP2 are linked to inhibited inflammatory mediator production in
macrophages. We found that aP2 expression in macrophages is repressed by unsaturated
fatty acids and acetylation of histones is likely to play a role in this repression. In
addition, aP2 may contribute to the induction of COX-2 expression by inflammatory
insults in macrophages.
In murine macrophage cell line, absence of aP2 markedly diminished proinflammatory cytokines (92). When THP-1 macrophages were incubated with the aP2
inhibitor, the production of pro-inflammatory cytokines including monocyte
chemoattractant protein-1 (MCP-1), IL-1 and IL-6 was significantly reduced (12). These
studies suggest a significant role of aP2 in inflammatory signaling in macrophages. In the
present study, both LPS and TNF significantly increased aP2 expression in RAW 264.7
macrophages. Although cell surface receptors for LPS and TNF are different,
downstream mediators that can transduce their signals can converge onto similar
pathways, including I Kappa B Kinases (IKK)/NF- B and MAPK/AP-1 pathways.
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Whether the induction of aP2 expression by LPS and TNF is mediated through the
pathways needs further investigation.
aP2 was initially thought to be controlled by PPARγ in adipocytes (97). It has
been suggested by Genolet et al. (36) that PPARγ agonists, such as long-chain fatty acids,
may regulate inflammatory pathways via both PPARγ-dependent and independent
mechanisms. The observation that LPS increases aP2 in the present study is
counterintuitive as LPS is known to inhibit PPAR transcriptional activity (98). If PPAR
represents the major regulator for aP2 expression in macrophages, down-regulation of
aP2 by LPS would be expected. Thus, another mechanism may exist by which LPS
induces aP2 expression independent of PPARγ. AP-1 and C/EBP are shown to regulate
aP2 expression in adipocytes and preadipocytes (80, 81, 99, 100). AP-1 is a more likely
candidate for a transcriptional regulator of macrophage aP2 responding to inflammatory
stimuli for the following reasons: first, AP-1 is one of the major transcriptional factors
that are sensitive to inflammatory insults to produce pro-inflammatory mediators (101,
102); second, aP2 promoter contains AP-1 binding element; and third, LPS stimulation is
shown to trigger signaling pathways leading to activation of MAPK (103-108) that can,
in turn, activate AP-1. Therefore, MAPK/AP-1 pathway could be involved in the
regulation of aP2 expression in macrophages.
Basal as well as LPS-induced aP2 expression in RAW 264.7 macrophage was
repressed by unsaturated fatty acids but not by saturated fatty acids. Therefore, we sought
to understand the mechanism for how unsaturated fatty acids can alter aP2 expression.
Posttranslational modifications in histones such as acetylation, phosphorylation and
ubiquitination are an important way to alter gene expression. Of the modifications,
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histone acetylation is best understood. To gain an insight into a potential role of HDAC in
the fatty acid regulation of aP2 expression, RAW 264.7 macrophages were treated with
TSA. We observed that the repressive effects of the unsaturated fatty acids on the basal as
well as LPS-induced aP2 expression were abrogated in the presence of TSA. The result is
supportive to the idea that histone modifications, particularly acetylation, can be a
mechanism by which fatty acids can alter aP2 expression in RAW 264.7 macrophages.
Of interest is that basal aP2 expression was markedly increased by TSA regardless of the
presence or absence of fatty acids suggesting that aP2 expression in RAW 264.7
macrophages is likely to be under active transrepression. Transcriptional factors namely
AP-1, NF- B and LXR (17, 19, 109-111) have shown to exert active transrepression of
gene expression through association with a co-repressor complex when they are not
activated by their agonists. Nuclear receptor corepressors (NCoR) and silencing mediator
for retinoid and thyroid receptor (SMRT) are essential components of a co-repressor
complex and HDAC3 is a well-known HDAC isoform to interact with NCoR and SMRT
(111-114). Therefore, we speculate that the co-repressor complex may be associated with
an unknown transcription factor in the promoter of aP2 to repress basal gene expression
in macrophages; and upon LPS stimulation, the co-repressor complex is dissociated to
induce gene expression.
HDAC activity was measured to assess whether fatty acids alter the activity.
Saturated fatty acids lowered HDAC activity. This observation is consistent with the
observation that saturated fatty acids can increase transcription of inflammatory mediated
such as COX-2 (39), in that a decrease in HDAC activity would coordinate with an
increase in transcription. Furthermore, saturated fatty acids lowering HDAC activity is
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also consistent with a trend seen in our data that saturated fatty acids can increase aP2
expression (data not shown). A similar parallel is seen with unsaturated fatty acids
increasing HDAC activity. When macrophages were transfected with aP2 siRNA and
treated with 18:2, there was a significant increase in HDAC activity. An increase in
HDAC activity would coordinate with a repression in transcription. The trend toward
significant for the negative control transfected cells treated with unsaturated fatty acid
would suggest that unsaturated fatty acids are capable of affecting the HDAC activity.
There was no significant differences in HDAC activity between the negative control and
aP2 transected cells but this could be due to the fact the HDAC activity kit used measured
universal HDAC activity and not a specific isoform. HDAC1 is the most abundance
HDAC isoform in macrophage (data not shown), it is possible that fatty acids may not
effect HDAC1 activity but could affect HDAC3 activity, which is the isoform believed to
be part of the corepressor complexes that can affect transcription (115). An assay to
measure universal HDAC activity would see HDAC1 overshadowing any effects that
could be present in HDAC3. However, we speculate that HDAC3 as part of a corepressor complex is influenced to continue or increase repression by unsaturated fatty
acids but alternatively removed in the presence of saturated fatty acids. The absence of
aP2 could further promote unsaturated fatty acids ability to influence the co-repressor
complex.
In summary, we have shown a significant up-regulation of aP2 by an
inflammatory insult, that unsaturated fatty acid repress both basal and induced aP2
expression, and that palmitic acid reduces HDAC activity in activated RAW 264.7
macrophage. This evidence suggests the involvement of HDAC and histone
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deacetylation state in the mechanisms for how unsaturated fatty acids modulate a
repression in LPS-activated macrophage. Lastly, a relationship between COX-2 and aP2
could be part of the mechanism for the anti-inflammatory effects of unsaturated fatty
acids seen in macrophage. We have provided here new information on the mechanisms
by which unsaturated fatty acids can regulate aP2 expression. Due to the high frequency
of obesity in the United States, deciphering the mechanism for the anti-inflammatory
properties of unsaturated fatty acid will allow for more appropriate and precise dietary
interventions to prevent chronic metabolic and inflammatory diseases.
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